PRICED Act
Latest action · Jun 23, 2016 Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Progress
Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.
- IntroducedJun 23, 2016
- Passed SenateNot reached
- Passed HouseNot reached
- To the PresidentNot reached
- Became lawNot reached
Summary
Price Relief, Innovation, and Competition for Essential Drugs Act or the PRICED Act
This bill amends the Public Health Service Act to allow biosimilars to be marketed seven years after the reference brand name biological product is licensed. Currently, brand name biological products are provided a 12-year marketing exclusivity period.
This shortened marketing exclusivity period applies only to biological products licensed by the Food and Drug Administration after enactment of this bill.Cosponsors 1
Members who signed on, in the order they did. All signed on Jun 23, 2016.
| Seat | Cosponsor | Signed on | |
|---|---|---|---|
| R-AZ | John McCain | Original | Jun 23, 2016 |
Actions 2
Everything that happened, newest first.
- Jun 23, 2016Introduced in Senate
- Jun 23, 2016Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Related bills 1
Companion bills and other measures the record links to this one.
| Bill | Title | Relationship | Latest action |
|---|---|---|---|
| HR 5573 | PRICED Act | Identical bill | Jun 23, 2016 |
Subjects
Assigned by the Library of Congress. Policy area: Health.
Text 1
Each version as it was printed, newest first.
- Jun 23, 2016Introduced in Senate
Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov.